Maria Christel Schneeweiss, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatitis, Atopic | 9 | 2024 | 654 | 4.660 |
Why?
|
| Psoriasis | 6 | 2024 | 901 | 2.670 |
Why?
|
| Hidradenitis Suppurativa | 4 | 2024 | 153 | 2.610 |
Why?
|
| Opportunistic Infections | 3 | 2020 | 389 | 1.720 |
Why?
|
| Alopecia Areata | 2 | 2024 | 107 | 1.550 |
Why?
|
| Vitiligo | 2 | 2022 | 89 | 1.540 |
Why?
|
| Pemphigoid, Bullous | 2 | 2023 | 110 | 1.530 |
Why?
|
| Conjunctivitis | 2 | 2022 | 158 | 1.440 |
Why?
|
| Venous Thromboembolism | 3 | 2023 | 1670 | 1.050 |
Why?
|
| Methotrexate | 4 | 2024 | 1726 | 0.960 |
Why?
|
| Conjunctivitis, Bacterial | 1 | 2022 | 24 | 0.840 |
Why?
|
| Hepatitis | 1 | 2024 | 227 | 0.820 |
Why?
|
| Bacterial Infections | 2 | 2020 | 1400 | 0.780 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2022 | 130 | 0.760 |
Why?
|
| Immunologic Factors | 5 | 2024 | 1580 | 0.730 |
Why?
|
| Systemic Vasculitis | 1 | 2020 | 37 | 0.720 |
Why?
|
| Scleroderma, Localized | 1 | 2020 | 79 | 0.710 |
Why?
|
| Thalidomide | 1 | 2024 | 890 | 0.650 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 866 | 0.650 |
Why?
|
| Sjogren's Syndrome | 1 | 2020 | 234 | 0.650 |
Why?
|
| Connective Tissue Diseases | 1 | 2020 | 264 | 0.600 |
Why?
|
| Phototherapy | 1 | 2020 | 377 | 0.570 |
Why?
|
| Colitis, Ulcerative | 3 | 2022 | 1911 | 0.530 |
Why?
|
| Arthritis, Psoriatic | 1 | 2017 | 215 | 0.490 |
Why?
|
| Arthritis | 1 | 2020 | 661 | 0.490 |
Why?
|
| Skin Diseases | 1 | 2022 | 1066 | 0.450 |
Why?
|
| Crohn Disease | 2 | 2022 | 2304 | 0.430 |
Why?
|
| Cohort Studies | 11 | 2023 | 40545 | 0.420 |
Why?
|
| Immunosuppressive Agents | 3 | 2022 | 4152 | 0.390 |
Why?
|
| Tuberculosis | 1 | 2024 | 1914 | 0.390 |
Why?
|
| Biological Products | 1 | 2020 | 859 | 0.380 |
Why?
|
| Propensity Score | 4 | 2023 | 1781 | 0.370 |
Why?
|
| Incidence | 6 | 2023 | 20948 | 0.330 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 2428 | 0.300 |
Why?
|
| Adjuvants, Immunologic | 2 | 2022 | 999 | 0.300 |
Why?
|
| Severity of Illness Index | 5 | 2023 | 15526 | 0.290 |
Why?
|
| Asthma | 1 | 2022 | 6010 | 0.220 |
Why?
|
| Registries | 1 | 2017 | 8090 | 0.200 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 3057 | 0.200 |
Why?
|
| Humans | 23 | 2024 | 743811 | 0.190 |
Why?
|
| Treatment Outcome | 7 | 2023 | 63042 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2024 | 7729 | 0.190 |
Why?
|
| Inflammation | 1 | 2020 | 10629 | 0.180 |
Why?
|
| Cyclosporine | 1 | 2022 | 788 | 0.170 |
Why?
|
| Arthralgia | 1 | 2023 | 456 | 0.170 |
Why?
|
| Administration, Cutaneous | 1 | 2020 | 710 | 0.160 |
Why?
|
| Pregnant Women | 1 | 2023 | 568 | 0.160 |
Why?
|
| Child | 6 | 2023 | 77637 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 5752 | 0.140 |
Why?
|
| Skin | 2 | 2022 | 4372 | 0.140 |
Why?
|
| Adult | 7 | 2024 | 213889 | 0.130 |
Why?
|
| Female | 10 | 2024 | 380020 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2015 | 6593 | 0.130 |
Why?
|
| Hyperkinesis | 1 | 2015 | 89 | 0.130 |
Why?
|
| Adolescent | 5 | 2021 | 85729 | 0.120 |
Why?
|
| Risk Assessment | 3 | 2020 | 23327 | 0.120 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2015 | 191 | 0.120 |
Why?
|
| Algorithms | 2 | 2024 | 13869 | 0.110 |
Why?
|
| Conduct Disorder | 1 | 2015 | 241 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 13980 | 0.110 |
Why?
|
| Risperidone | 1 | 2015 | 383 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4422 | 0.110 |
Why?
|
| Middle Aged | 6 | 2024 | 213241 | 0.100 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2017 | 1204 | 0.100 |
Why?
|
| Young Adult | 3 | 2021 | 56392 | 0.090 |
Why?
|
| Male | 7 | 2024 | 349776 | 0.090 |
Why?
|
| Software | 1 | 2023 | 4440 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2023 | 12020 | 0.090 |
Why?
|
| United States | 3 | 2022 | 69859 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2015 | 1101 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 15067 | 0.080 |
Why?
|
| Thiazoles | 1 | 2015 | 1482 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2020 | 2492 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2022 | 9139 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2024 | 4467 | 0.070 |
Why?
|
| Prevalence | 1 | 2024 | 15211 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2760 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9272 | 0.070 |
Why?
|
| Biopsy | 1 | 2017 | 6750 | 0.060 |
Why?
|
| Risk Factors | 2 | 2023 | 72252 | 0.060 |
Why?
|
| Piperazines | 1 | 2015 | 2487 | 0.060 |
Why?
|
| Boston | 1 | 2017 | 9310 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2015 | 2265 | 0.060 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 2684 | 0.060 |
Why?
|
| Aged | 3 | 2020 | 163178 | 0.060 |
Why?
|
| Comorbidity | 1 | 2017 | 10380 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2015 | 3744 | 0.050 |
Why?
|
| Research Design | 1 | 2017 | 5983 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 29140 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2015 | 6259 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2015 | 3044 | 0.040 |
Why?
|
| Mass Screening | 1 | 2015 | 5251 | 0.040 |
Why?
|
| Random Allocation | 1 | 2023 | 2429 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7270 | 0.040 |
Why?
|
| Gastrointestinal Agents | 1 | 2022 | 494 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2022 | 2617 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2015 | 40964 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2021 | 77410 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2023 | 6188 | 0.020 |
Why?
|